On this page
Quick Reference
Overview and Recommendations
Background
- •Gastric cancer surveillance after curative treatment aims to detect asymptomatic recurrence at a potentially salvageable stage, identify metachronous primary tumors, and manage treatment-related complications. The highest risk of recurrence is within the first 2-3 years, especially for patients with advanced stage, ypN+ status, or R1 resection.
- •Approximately 50% of patients with curatively treated gastric cancer will develop recurrence, with locoregional and peritoneal patterns being most common. Early detection via surveillance improves salvage rates and overall survival, though the optimal schedule is not defined by a single landmark trial.
- •High-risk hereditary syndromes requiring intensive surveillance include hereditary diffuse gastric cancer (HDGC) due to CDH1 mutations, with a cumulative gastric cancer risk of 70% in males and 56% in females by age 80, and Lynch syndrome (MMR gene mutations), where gastric cancer risk is significantly elevated (SIR 9.78).
- •H. pylori eradication reduces the incidence of metachronous gastric cancer after endoscopic resection by approximately 50% (HR 0.50, 95% CI 0.26-0.94), as shown in a randomized trial. Dietary factors also play a role: higher vegetable intake is associated with reduced distal gastric cancer risk in men (HR 0.78).
- •Chemotherapy-induced peripheral neuropathy (CIPN) is the most common late toxicity, affecting long-term survivors. In the Netherlands Cancer Registry cohort, CIPN scores did not return to baseline after curative chemotherapy or palliative therapy, with adjusted mean scores at 6 months of 16.0 for curative chemotherapy and 25.4 for palliative therapy.
- •Surveillance also encompasses nutritional monitoring (vitamin B12, iron, vitamin D), evaluation for late surgical complications (dumping syndrome, reflux, bone demineralization), and psychosocial support. A combined psychological and sleep intervention has been shown to improve 2-year disease-free survival (81.2% vs 68.5%) and overall survival (88.5% vs 76.7%).
Evaluation
- •Suspect recurrence in any patient with curatively treated gastric cancer who presents with new or worsening dysphagia, early satiety, unexplained weight loss, abdominal pain, jaundice, or gastrointestinal bleeding. These symptoms should trigger immediate evaluation regardless of scheduled surveillance.
- •Examine for signs of peritoneal carcinomatosis (abdominal distension, palpable masses, ascites), supraclavicular lymphadenopathy (Virchow node), and hepatomegaly. Also assess for late toxicities: peripheral neuropathy (sensory deficits, pain), dumping syndrome (postprandial vasomotor symptoms, diarrhea), and nutritional deficiencies.
- •Order contrast-enhanced CT of the thorax and abdomen as the primary imaging modality for detecting locoregional and distant recurrence. For patients with curatively treated disease, CT should be performed every 6-12 months for the first 2-3 years, then annually. In the advanced disease setting, CT every 6-12 weeks is recommended for patients still candidates for further therapy.
- •Perform upper endoscopy with systematic random biopsies for intraluminal recurrence, especially in patients with hereditary diffuse gastric cancer (CDH1 carriers). In a prospective cohort, 50% of first diagnoses of signet ring cell carcinoma were made from random biopsies; omitting them would lead to a 42% under-diagnosis rate.
- •For patients who have undergone endoscopic resection of early gastric cancer, routine surveillance endoscopy is essential to detect metachronous lesions. H. pylori eradication reduces metachronous cancer risk by half, but surveillance remains mandatory.
- •Use risk stratification to guide intensity of surveillance. The seven-gene signature GC-RiskAssigner identifies high-risk patients (median OS 10.2 months) vs low-risk (median OS 80.9 months; HR 5.1). Patients with ypN+ or R1 status after neoadjuvant chemotherapy and surgery have median disease-free survival of 20.8 months and should be considered for more frequent imaging.
- •Confirm recurrence with biopsy: endoscopic biopsy of visible lesions or random biopsies of the anastomosis/remnant stomach for intraluminal recurrence; CT-guided biopsy or laparoscopic sampling for distant recurrence. Staging with PET-CT or diagnostic laparoscopy should be performed before treatment planning.
- •Assess for late toxicities during surveillance visits. Screen for CIPN using validated questionnaires (e.g., EORTC QLQ-C30). Check hemoglobin, vitamin B12, iron, vitamin D, and calcium levels, especially after gastrectomy. Evaluate for dumping syndrome, reflux, and bone demineralization.
- •Evaluate psychosocial status: screen for anxiety, depression, and sleep disturbance using HADS-A, HADS-D, and PSQI. A combined psychological and sleep intervention significantly improved these outcomes and enhanced immune function in a randomized trial.
- •For hereditary syndromes, document family history and refer for genetic counselling. In CDH1 carriers, discuss risk-reducing total gastrectomy and annual endoscopic surveillance if surgery is deferred. In Lynch syndrome, recommend esophagogastroduodenoscopy starting at age 35 regardless of family history.
Management
- •Implement a structured surveillance schedule: for curatively treated gastric cancer, perform CT thorax/abdomen every 6 months for the first 2-3 years, then annually. Individualize frequency based on stage, histology, and risk stratification (e.g., GC-RiskAssigner, ypN+ status).
- •Perform upper endoscopy with random biopsies at intervals determined by risk: annually for CDH1 carriers deferring gastrectomy; every 6-12 months for patients after endoscopic resection of early gastric cancer. In Lynch syndrome, begin endoscopy at age 35 with 1-3 year intervals.
- •Administer H. pylori eradication therapy for patients with early gastric cancer after endoscopic resection to reduce metachronous cancer risk. Use a standard triple therapy (proton pump inhibitor + amoxicillin + clarithromycin) or bismuth-based quadruple therapy, depending on local resistance patterns.
- •Monitor for CIPN: switch to fluoropyrimidine maintenance (e.g., S-1) to reduce neuropathy. In the MATEO trial, grade ≥2 peripheral sensory polyneuropathy occurred in 9.4% of patients on S-1 maintenance vs 36.7% on platinum-based combination. Manage established CIPN with dose reduction, duloxetine, or physical therapy.
- •Manage nutritional deficiencies: prescribe vitamin B12 1000 μg intramuscularly monthly, elemental iron 150-200 mg/day orally, and vitamin D 800-1000 IU/day. Monitor calcium levels and consider calcium supplementation. Refer to a clinical dietitian for individualized dietary counselling emphasizing small, frequent meals (5-6/day) with adequate protein and calorie intake.
- •Counsel all postgastrectomy patients on dumping syndrome management: avoid high-sugar meals, eat small frequent meals, separate liquid and solid intake, and consider acarbose or octreotide for refractory cases. Educate on recognition of bile reflux and internal herniation.
- •Integrate psychological and sleep interventions into routine surveillance. Offer cognitive behavioral therapy, sleep hygiene education, and melatonin supplementation (3-5 mg at bedtime). A randomized trial showed this approach improved 2-year disease-free survival (81.2% vs 68.5%) and overall survival (88.5% vs 76.7%).
- •For weight management, provide dietary counselling. While intensive counseling (5 sessions) did not significantly reduce weight loss compared to a single session (mean weight change - vs - at 12 months), individualized counselling focusing on calorie needs and symptom assessment reduced BMI loss at 30, 60, and 90 days. Consider mobile app-based coaching (e.g., Noom) for sustained engagement.
- •Refer patients with hereditary gastric cancer syndromes (CDH1, Lynch) to a genetics service for family screening and discussion of risk-reducing total gastrectomy. Female CDH1 carriers also have a 42% breast cancer risk; recommend breast MRI screening starting at age 30.
- •Avoid long-term opioid use. In opioid-naïve patients, 10.4% develop new persistent opioid use after curative-intent surgery; this rises to 15-21% in those receiving adjuvant chemotherapy. Counsel on opioid risks and implement a tapering plan.
- •Refer to survivorship clinic for coordinated multidisciplinary care. Use validated HRQoL tools (EORTC QLQ-C30, FACT-Ga) to screen for late toxicities. Early referral to physical therapy, occupational therapy, and psychosocial support can prevent irreversible functional decline.
- •For patients with confirmed recurrence, management is guided by pattern of recurrence and prior treatments. Options include systemic therapy (chemotherapy, targeted therapy, immunotherapy), surgical resection, radiation, or palliative care. Staging with PET-CT and diagnostic laparoscopy is recommended before treatment planning.
Board Review — High Yield
- •H. pylori eradication after endoscopic resection, reduces metachronous gastric cancer risk by 50% (HR 0.50).
- •Random biopsies in CDH1 carriers, 50% of first signet ring cell cancers detected by random biopsies; omitting leads to 42% under-diagnosis.
- •CIPN does not return to baseline, after curative chemotherapy, CIPN scores remain elevated; switch to S-1 maintenance reduces grade ≥2 neuropathy (9.4% vs 36.7%).
- •Psychological + sleep intervention, improved 2-year DFS (81.2% vs 68.5%) and OS (88.5% vs 76.7%) in post-gastrectomy patients.
- •GC-RiskAssigner, 7-gene signature stratifies patients into high-risk (median OS 10.2 months) vs low-risk (80.9 months); HR 5.1.
- •Weight loss after gastrectomy, 98.4% of CDH1 carriers lose weight; intensive dietary counselling may not reduce weight loss more than a single session, but individualized counselling reduces BMI loss.
- •Lynch syndrome gastric cancer risk, SIR 9.78; recommend EGD starting at age 35.
- •New persistent opioid use, occurs in 10.4% of opioid-naïve patients after curative surgery; higher with adjuvant chemotherapy.
- •HRQoL maintenance, ramucirumab + paclitaxel (RAINBOW) and nivolumab + chemo (CheckMate 649) reduce risk of definitive HRQoL deterioration.
- •Multimodal prehabilitation, reduces postoperative complications (pneumonia, delirium) in elderly patients.
Deep Dive — Evidence Details
Surveillance Schedule
- ▸H. pylori eradication reduces gastric cancer risk by ~one-third [4].
- ▸After curative treatment, CT thorax/abdomen every 6-12 months for first 2-3 years is recommended [4].
Primary Prevention and Screening
Helicobacter pylori eradication reduces gastric cancer incidence: a population-based programme in Taiwan reduced incidence by 53%, and a meta-analysis of six trials found ~one-third risk reduction [4]A1c. Higher vegetable intake reduces distal gastric cancer risk in men (HR 0.78, 95% CI 0.63-0.97) [6]B2b; high red/processed meat increases oesophageal SCC risk (HR 3.47) [7]B2b. Screening is recommended only in high-incidence regions (e.g., East Asia) [4]A1c. For hereditary diffuse gastric cancer (HDGC) with CDH1 variant, annual endoscopic surveillance with high-definition endoscopy is advised if deferring prophylactic [5]A1c. For MMR carriers, gastric cancer risk is elevated (SIR 9.78) [12]C4; consider EGD surveillance.
Surveillance after Curative Treatment
Regular follow-up is recommended for symptom investigation, psychological support, and early recurrence detection [III, B] [4]A1c. Typical schedule: clinic visits and contrast-enhanced and abdomen every 6-12 months for first 2-3 years, then annually [4]A1c. Nutritional monitoring includes vitamin B12, iron, and vitamin D assessment.
Patient Education
Counsel on adherence to surveillance, symptom reporting (dysphagia, weight loss, abdominal pain, fatigue), and recognition of late toxicities. Dietary support and psychological care are recommended [V, B] [4]A1c.
Pearl: For patients with curatively treated gastric cancer, the first 2-3 years carry the highest risk of recurrence; a protocol of CT thorax/abdomen every 6 months during this period, individualised by stage and histology, aligns with expert consensus and is the window in which most salvageable recurrences are detected.
Detection of Recurrence
- ▸Random biopsies detect 50% of signet ring cell carcinomas in HDGC [31].
- ▸Seven-gene signature stratifies OS (HR 5.1) [23].
Yield of Endoscopic Surveillance
Endoscopy detects intraluminal recurrence. In HDGC, random biopsies are critical: in a prospective cohort, 3% of 38,803 biopsies were positive for invasive signet ring cell carcinoma; surveillance detected occult cancer in 74/76 patients [30]C4. Another study found first diagnosis from random biopsies in 50% of patients; omitting random biopsies would under-diagnose 42% [31]B2b.
Detection of Metachronous Cancer After Endoscopic Resection
In a randomized trial, H. pylori eradication reduced metachronous gastric cancer (7.2% vs 13.4%; HR 0.50, 95% CI 0.26-0.94) [35]A1b. Surveillance endoscopy remains essential.
Role of Risk Stratification
A seven-gene signature (GC-RiskAssigner) stratified median OS: 10.2 months (high-risk) vs 80.9 months (low-risk); HR 5.1 [23]A1b. ypN+ or R1 status after neoadjuvant therapy also indicates high recurrence risk (median DFS 20.8 months) [20]B2b.
Confirmatory Workup
Suspected recurrence requires confirmatory biopsy (endoscopic, CT-guided, or laparoscopic). Staging with PET-CT or diagnostic laparoscopy is advised before treatment planning.
Pearl: H. pylori eradication reduces metachronous gastric cancer by half after endoscopic resection, but routine surveillance endoscopy remains essential [35]A1b.
Late Toxicity and Survivorship
- ▸CIPN does not return to baseline after curative therapy [37].
- ▸Switch to fluoropyrimidine maintenance reduces neuropathy [52].
Chemotherapy-Induced Peripheral Neuropathy (CIPN)
CIPN is the most common late toxicity; scores do not return to baseline after curative or palliative therapy [37]B2b. Adjusted mean CIPN at 6 months: 8.3 (chemoradiotherapy), 16.0 (chemotherapy curative), 25.4 (palliative) [37]B2b. Switch to fluoropyrimidine maintenance reduces neuropathy (9.4% vs 36.7% for platinum-based) [52]B2b.
Other Treatment-Related Toxicities
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Grade 3-4 with apatinib; more common in women [40]A1b[44]A1b | Dose reduction | Supportive care, dose interruption | |
| Anemia | More frequent in older patients [44]A1b | Monitor hemoglobin | Transfusion, ESAs |
| Stomatitis/mucositis | Grade 3-4: 21% DCF vs 27% CF [48]B2b | Oral hygiene, cryotherapy | Topical anesthetics, pain management |
| Neutropenia/febrile neutropenia | Grade 3-4: 82% DCF vs 57% CF [48]B2b | G-CSF prophylaxis | Dose reduction, G-CSF, antibiotics |
| Radiation-related late toxicity | Similar between arms in TOPGEAR [53]B2b | Limit field, conformal techniques | Bowel management, nutritional support |
| Surgical late effects (dumping, reflux, malnutrition) | Worse after standard gastrectomy [18]A1b | Consider sentinel node navigation surgery [18]A1b | Dietary counseling, small frequent meals, supplementation |
| Fatigue | Baseline score 39.1/100 [38]A1b | Screen for depression, anemia, hypothyroidism | Exercise, energy conservation |
Survivorship and Quality of Life
Postoperative chemotherapy yields better physical functioning and less dysphagia than chemoradiotherapy [3]A1b. Ramucirumab + paclitaxel delays performance status deterioration (HR 0.802) [38]A1b. Nivolumab + chemo reduces HRQoL deterioration [41]A1b. Regorafenib delays global QoL deterioration (HR 0.68) [47]B2b. Multidisciplinary survivorship care is recommended [36]A1c.
Pearl: Early recognition of CIPN and proactive management of nutritional deficits, including iron, vitamin B12, and calcium, are key to preserving functional status and quality of life in long-term survivors of gastric cancer.
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Chemotherapy-induced peripheral neuropathy | Adjusted mean score 16.0 (curative) and 25.4 (palliative) at 6 months [37]B2b; ≥grade 2 neuropathy 9.4% with S-1 vs 36.7% with platinum [52]B2b | Consider S-1 maintenance after 3 months induction [52]B2b; early recognition [37]B2b | Dose reduction, switch to less neurotoxic regimen, gabapentinoids, physical therapy |
| Hand-foot syndrome | Grade 3-4 with apatinib [40]A1b; more common in women [44]A1b | Dose reduction of apatinib; avoid heat/friction | Supportive care, topical emollients, dose interruption |
| Anemia | More frequent in older patients [44]A1b | Monitor hemoglobin | Transfusion, erythropoiesis-stimulating agents |
| Stomatitis/mucositis | Grade 3-4: 21% DCF vs 27% CF [48]B2b; lower with IF vs CF [39]A1b | Oral hygiene, cryotherapy | Topical anesthetics, pain management, dose reduction |
| Neutropenia/febrile neutropenia | Grade 3-4 neutropenia: 82% DCF vs 57% CF; complicated neutropenia 29% vs 12% [48]B2b | G-CSF prophylaxis | Dose reduction, G-CSF, antibiotics |
| Radiation-related late toxicity | Grade 3-4 events: 41% with chemoradiotherapy vs 48% with chemotherapy [46]A1b | Conformal radiation, limit field | Bowel management, anti-diarrheals, nutritional support |
| Surgical late effects (dumping, reflux, malnutrition) | Standard gastrectomy worse than stomach-preserving surgery for nutrition [18]A1b | Consider sentinel node navigation surgery in early gastric cancer [18]A1b | Dietary counseling, small frequent meals, iron/B12/calcium supplementation |
| Fatigue | Baseline fatigue score 39.1 [38]A1b; lethargy 19% DCF vs 14% CF [48]B2b | Screen for depression, anemia, hypothyroidism | Exercise, energy conservation, treat underlying causes |
Patient Counselling
- ▸Psychological and sleep intervention improved survival (DFS 81.2% vs 68.5%) [63].
- ▸CDH1 carriers have 70% (male) and 56% (female) gastric cancer risk by age 80 [71].
Dietary Counselling and Weight Management
Postgastrectomy weight loss is nearly universal. Intensive nutritional counselling (5 sessions) did not reduce weight loss vs simplified (1 session) (mean difference 0.09 percentage points, 95% CI -1.43 to 1.60) [61]A1b, but individualized counselling reduced BMI loss at 30, 60, and 90 days [69]A1b. Loss-framed messages improve adherence [64]A1b. Mobile app coaching (Noom) improved dyspnea and eating restriction [60]A1b.
Symptom Awareness and Reporting
Teach patients to report new dysphagia, early satiety, unexplained weight loss, abdominal pain, jaundice, or GI bleeding. New persistent opioid use occurs in 10.4% of opioid-naïve patients [68]D5; counsel on tapering.
Lifestyle and Psychological Support
A combined psychological and sleep intervention (CBT, sleep hygiene, melatonin) improved anxiety (HADS-A 12.3→7.1), depression (11.8→6.5), sleep quality (PSQI 10.5→6.2), and survival (2-year DFS 81.2% vs 68.5%, OS 88.5% vs 76.7%) [63]A1b. Multimodal prehabilitation reduces postoperative complications [70]B2b[73]B3b.
Hereditary Risk Assessment and Family Screening
For CDH1 carriers, cumulative gastric cancer risk by age 80: 70% (males), 56% (females); female carriers also have 42% breast cancer risk [71]D5. Lynch syndrome carriers should start gastric surveillance at age 35 [66]D5. Multigene panel testing is recommended for eligible patients [58]A1c.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Is intensive nutritional counselling superior for weight preservation? | No; MD 0.09% [61]A1b | Yes; individualized counselling reduced BMI loss [69]A1b | Moderate, conflicting RCTs | Optimal intensity unclear; tailored approaches benefit total/proximal gastrectomy |
| Should psychological/sleep interventions be standard? | Yes; improved survival (DFS 81.2% vs 68.5%) [63]A1b | No formal guideline recommendation | Moderate, single RCT | Consider integrating for distressed patients |
Pearl: For postgastrectomy patients, a single session of dietary counselling may be as effective as intensive follow-up for weight preservation, but individualized counselling reduces BMI loss in patients undergoing total or proximal gastrectomy [61]A1b[69]A1b; integrating psychological and sleep interventions can improve not only quality of life but also survival outcomes [63]A1b.
| Domain | Message | Evidence |
|---|---|---|
| Dietary | Aim for 5-6 small meals/day; prioritize protein (1.2-1.5 g/kg/day) and calorie goals (25-30 kcal/kg/day); expect gradual weight stabilization by 12-18 months | [61]A1b[69]A1b |
| Symptom reporting | Report new dysphagia, early satiety, unexplained weight loss, abdominal pain, jaundice, or GI bleeding immediately | [67]D5 |
| Opioid use | Opioid-naïve patients have a 10.4% risk of new persistent opioid use; adjuvant chemotherapy increases risk to 15-21% | [68]D5 |
| Psychological | Screen for anxiety, depression, and sleep disturbance; consider referral for CBT and sleep hygiene education | [63]A1b |
| Lifestyle | Encourage smoking cessation, alcohol moderation, and regular physical activity; multimodal prehabilitation reduces complications | [70]B2b[73]B3b |
| Hereditary risk | Offer genetic counselling to at-risk relatives; CDH1 carriers need gastric and breast surveillance; Lynch syndrome carriers need gastric surveillance starting at age 35 | [54]A1c[66]D5[71]D5 |
References
- [1]
Muro K, Van Cutsem E, Narita Y et al.. “Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 30475956 ↗
L1GUIDELINECited in: Surveillance Schedule - [2]
Dijksterhuis WPM, Latenstein AEJ, van Kleef JJ et al.. “Cachexia and Dietetic Interventions in Patients With Esophagogastric Cancer: A Multicenter Cohort Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33418527 ↗
L2PROSPECTIVE_COHORTCited in: Surveillance Schedule - [3]
van Amelsfoort RM, Walraven I, Kieffer J et al.. “Quality of Life Is Associated With Survival in Patients With Gastric Cancer: Results From the Randomized CRITICS Trial.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35276669 ↗
L1RCTCited in: Surveillance Schedule, Late Toxicity and Survivorship - [4]
Shitara K, Fleitas T, Kawakami H et al.. “Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer.” ESMO open (2024). PMID: 38458658 ↗
L1GUIDELINECited in: Surveillance Schedule - [5]
Blair VR, McLeod M, Carneiro F et al.. “Hereditary diffuse gastric cancer: updated clinical practice guidelines.” The Lancet. Oncology (2020). PMID: 32758476 ↗
L1GUIDELINECited in: Surveillance Schedule - [6]
Shimazu T, Wakai K, Tamakoshi A et al.. “Association of vegetable and fruit intake with gastric cancer risk among Japanese: a pooled analysis of four cohort studies.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24618149 ↗
L2PROSPECTIVE_COHORTCited in: Surveillance Schedule - [7]
Keszei AP, Schouten LJ, Goldbohm RA et al.. “Red and processed meat consumption and the risk of esophageal and gastric cancer subtypes in The Netherlands Cohort Study.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22351741 ↗
L2PROSPECTIVE_COHORTCited in: Surveillance Schedule - [8]
Janjigian YY, Shitara K, Ajani JA et al.. “Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 41687718 ↗
L1RCTCited in: Surveillance Schedule - [9]
Park SH, Lim DH, Sohn TS et al.. “A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33278599 ↗
L1RCTCited in: Surveillance Schedule, Detection of Recurrence - [10]
Fazio N, Biffi R, Maibach R et al.. “Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26712905 ↗
L1RCTCited in: Surveillance Schedule - [11]
Ryu MH, Baba E, Lee KH et al.. “Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26216386 ↗
L1RCTCited in: Surveillance Schedule, Detection of Recurrence - [12]
Win AK, Young JP, Lindor NM et al.. “Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22331944 ↗
L4PROSPECTIVE_COHORTCited in: Surveillance Schedule - [13]
Kang YK, Yook JH, Park YK et al.. “PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34133211 ↗
L1RCTCited in: Surveillance Schedule - [14]
Yoshida K, Kodera Y, Kochi M et al.. “Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30925125 ↗
L1RCTCited in: Surveillance Schedule - [15]
Smalley SR, Benedetti JK, Haller DG et al.. “Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22585691 ↗
L1RCTCited in: Surveillance Schedule - [16]
Kang YK, Kim HD, Yook JH et al.. “Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38996201 ↗
L1RCTCited in: Surveillance Schedule - [17]
Lee CK, Kim HS, Jung M et al.. “Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37883723 ↗
L1RCTCited in: Surveillance Schedule - [18]
Kim YW, Min JS, Yoon HM et al.. “Laparoscopic Sentinel Node Navigation Surgery for Stomach Preservation in Patients With Early Gastric Cancer: A Randomized Clinical Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35324317 ↗
L1RCTCited in: Surveillance Schedule, Detection of Recurrence, Late Toxicity and Survivorship - [19]
Fuchs CS, Niedzwiecki D, Mamon HJ et al.. “Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28976791 ↗
L1RCTCited in: Surveillance Schedule, Detection of Recurrence - [20]
Lordick F, Mauer ME, Stocker G et al.. “Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39542422 ↗
L2RCT_PHASE2Cited in: Surveillance Schedule, Detection of Recurrence - [21]
Kim HS, Kim HJ, Kim SY et al.. “Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23942775 ↗
L2SR_COHORTCited in: Detection of Recurrence - [22]
Bang YJ, Ruiz EY, Van Cutsem E et al.. “Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 30052729 ↗
L1RCTCited in: Detection of Recurrence - [23]
Smyth EC, Nyamundanda G, Cunningham D et al.. “A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 30481267 ↗
L1RCTCited in: Detection of Recurrence - [24]
Jeung HC, Moon YW, Rha SY et al.. “Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 18029971 ↗
L1RCTCited in: Detection of Recurrence - [25]
Kang YK, Ryu MH, Park SH et al.. “Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29438463 ↗
L1RCTCited in: Detection of Recurrence - [26]
Shitara K, Ito S, Misawa K et al.. “Genetic polymorphism of IGF-I predicts recurrence in patients with gastric cancer who have undergone curative gastrectomy.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21690232 ↗
L3COHORTCited in: Detection of Recurrence - [27]
Shen L, Shan YS, Hu HM et al.. “Management of gastric cancer in Asia: resource-stratified guidelines.” The Lancet. Oncology (2013). PMID: 24176572 ↗
L1GUIDELINECited in: Detection of Recurrence - [28]
Lee J, Lim DH, Kim S et al.. “Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 22184384 ↗
L1RCTCited in: Detection of Recurrence - [29]
Van Cutsem E, Boni C, Tabernero J et al.. “Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25416687 ↗
L2RCT_PHASE2Cited in: Detection of Recurrence - [30]
Asif B, Sarvestani AL, Gamble LA et al.. “Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer: a prospective cohort study.” The Lancet. Oncology (2023). PMID: 36990610 ↗
L4PROSPECTIVE_COHORTCited in: Detection of Recurrence - [31]
Lee CYC, Olivier A, Honing J et al.. “Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: a prospective 16-year longitudinal cohort study.” The Lancet. Oncology (2022). PMID: 36509094 ↗
L2PROSPECTIVE_COHORTCited in: Detection of Recurrence - [32]
Han MA, Oh MG, Choi IJ et al.. “Association of family history with cancer recurrence and survival in patients with gastric cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22271486 ↗
L3COHORTCited in: Detection of Recurrence - [33]
Wu CW, Hsiung CA, Lo SS et al.. “Nodal dissection for patients with gastric cancer: a randomised controlled trial.” The Lancet. Oncology (2006). PMID: 16574546 ↗
L1RCTCited in: Detection of Recurrence - [34]
Sakuramoto S, Sasako M, Yamaguchi T et al.. “Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.” The New England journal of medicine (2007). PMID: 17978289 ↗
L1RCTCited in: Detection of Recurrence - [35]
Choi IJ, Kook MC, Kim YI et al.. “Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer.” The New England journal of medicine (2018). PMID: 29562147 ↗
L1RCTCited in: Detection of Recurrence - [36]
Ajani JA, D'Amico TA, Bentrem DJ et al.. “Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35130500 ↗
L1GUIDELINECited in: Late Toxicity and Survivorship - [37]
van Velzen MJM, Pape M, Sprangers MAG et al.. “Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38977016 ↗
L2PROSPECTIVE_COHORTCited in: Late Toxicity and Survivorship - [38]
Al-Batran SE, Van Cutsem E, Oh SC et al.. “Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 26747859 ↗
L1RCTCited in: Late Toxicity and Survivorship - [39]
Dank M, Zaluski J, Barone C et al.. “Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.” Annals of oncology : official journal of the European Society for Medical Oncology (2008). PMID: 18558665 ↗
L1RCTCited in: Late Toxicity and Survivorship - [40]
Li J, Qin S, Xu J et al.. “Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26884585 ↗
L1RCTCited in: Late Toxicity and Survivorship - [41]
Moehler M, Xiao H, Blum SI et al.. “Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37713657 ↗
L1RCTCited in: Late Toxicity and Survivorship - [42]
Park SH, Nam E, Park J et al.. “Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 18083691 ↗
L2RCT_PHASE2Cited in: Late Toxicity and Survivorship - [43]
Janjigian YY, Kawazoe A, Xu J et al.. “Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial.” ESMO open (2025). PMID: 41033280 ↗
L1RCTCited in: Late Toxicity and Survivorship - [44]
Fazio R, Randon G, Bergamo F et al.. “Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial.” ESMO open (2025). PMID: 40540760 ↗
L1RCTCited in: Late Toxicity and Survivorship - [45]
Van Cutsem E, Valderrama A, Bang YJ et al.. “Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study.” ESMO open (2021). PMID: 34371381 ↗
L1RCTCited in: Late Toxicity and Survivorship - [46]
Cats A, Jansen EPM, van Grieken NCT et al.. “Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.” The Lancet. Oncology (2018). PMID: 29650363 ↗
L1RCTCited in: Late Toxicity and Survivorship - [47]
Pavlakis N, Shitara K, Sjoquist K et al.. “INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39365958 ↗
L2RCT_PHASE2Cited in: Late Toxicity and Survivorship - [48]
Van Cutsem E, Moiseyenko VM, Tjulandin S et al.. “Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 17075117 ↗
L2RCT_PHASE2Cited in: Late Toxicity and Survivorship - [49]
Roth AD, Fazio N, Stupp R et al.. “Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17664469 ↗
L2RCT_PHASE2Cited in: Late Toxicity and Survivorship - [50]
Raimondi A, Lonardi S, Murgioni S et al.. “Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39637944 ↗
L2NON_RANDOMIZED_TRIALCited in: Late Toxicity and Survivorship - [51]
Brenner B, Shah MA, Karpeh MS et al.. “A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16788003 ↗
L2NON_RANDOMIZED_TRIALCited in: Late Toxicity and Survivorship - [52]
Stocker G, Lorenzen S, Ettrich T et al.. “S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial.” ESMO open (2023). PMID: 37270871 ↗
L2RCT_PHASE2Cited in: Late Toxicity and Survivorship - [53]
Leong T, Smithers BM, Michael M et al.. “Preoperative Chemoradiotherapy for Resectable Gastric Cancer.” The New England journal of medicine (2024). PMID: 39282905 ↗
L2RCT_PHASE2Cited in: Late Toxicity and Survivorship - [54]
Daly MB, Pal T, Berry MP et al.. “Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33406487 ↗
L1GUIDELINECited in: Patient Counselling - [55]
McNair AG, Brookes ST, Davis CR et al.. “Communicating the results of randomized clinical trials: do patients understand multidimensional patient-reported outcomes?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20065187 ↗
L1RCTCited in: Patient Counselling - [56]
Kim JH, Kim HS, Seo WY et al.. “External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21566150 ↗
L4RETROSPECTIVE_COHORTCited in: Patient Counselling - [57]
Fan W, Tao Y, Shi J et al.. “Effects of New Media-Based Education on the Treatment of Helicobacter pylori Infection: Systematic Review and Meta-Analysis.” Journal of medical Internet research (2025). PMID: 41130587 ↗
L1SR_MA_RCTCited in: Patient Counselling - [58]
Carballal S, Balaguer F, Bujanda L et al.. “Use of multi-gene panels in patients at high risk of hereditary digestive cancer: position statement of AEG, SEOM, AEGH and IMPaCT-GENÓMICA consortium.” Gastroenterologia y hepatologia (2023). PMID: 37315767 ↗
L1GUIDELINECited in: Patient Counselling - [59]
Xu J, Dong GL, Sheng L. “Roy adaptation model-based patient education for elderly patients undergoing laparoscopic radical gastrectomy.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 41524904 ↗
L1RCTCited in: Patient Counselling - [60]
Eom BW, Han M, Yoon HM et al.. “Improvement in Quality of Life After Early Interactive Human Coaching via a Mobile App in Postgastrectomy Patients With Gastric Cancer: Prospective Randomized Controlled Trial.” JMIR mHealth and uHealth (2025). PMID: 41411643 ↗
L1RCTCited in: Patient Counselling - [61]
Lee AR, Bae JM, Choi MG et al.. “Nutritional Counseling for Patients With Gastric Cancer After Subtotal Gastrectomy: A Randomized Clinical Trial.” Journal of gastric cancer (2025). PMID: 41093778 ↗
L1RCTCited in: Patient Counselling - [62]
Zhou H, Bao R, Qiu L et al.. “Self-efficacy centered comprehensive interventions and effects in patients undergoing radical surgery for gastric cancer.” Frontiers in medicine (2025). PMID: 40776917 ↗
L1RCTCited in: Patient Counselling - [63]
Wang G, Pan S. “Psychological Interventions and Sleep Improvement for Patients with Gastric Cancer: Effects on Immune Function, Inflammation, and Tumor Progression-A Randomized Controlled Trial.” Annals of surgical oncology (2025). PMID: 40603815 ↗
L1RCTCited in: Patient Counselling - [64]
Lee JY, Oh EG, Jang Y et al.. “Effectiveness of self-management program for gastric cancer patients: A randomized controlled trial comparing gain vs. loss message framing.” Patient education and counseling (2024). PMID: 39047331 ↗
L1RCTCited in: Patient Counselling - [65]
Li Q, Chen C, Wang X. “Perioperative nutritional interventions for gastric cancer patients: a meta-analysis of surgical outcomes.” Frontiers in nutrition (2025). PMID: 41235306 ↗
L1SR_MA_RCTCited in: Patient Counselling - [66]
Goecke T, Schulmann K, Engel C et al.. “Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16908935 ↗
L5OTHERCited in: Patient Counselling - [67]
Gallanis AF, Gamble LA, Samaranayake SG et al.. “Costs of Cancer Prevention: Physical and Psychosocial Sequelae of Risk-Reducing Total Gastrectomy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37903316 ↗
L5OTHERCited in: Patient Counselling - [68]
Lee JS, Hu HM, Edelman AL et al.. “New Persistent Opioid Use Among Patients With Cancer After Curative-Intent Surgery.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29048972 ↗
L5OTHERCited in: Patient Counselling - [69]
Yan H, He F, Wei J et al.. “Effects of individualized dietary counseling on nutritional status and quality of life in post-discharge patients after surgery for gastric cancer: A randomized clinical trial.” Frontiers in oncology (2023). PMID: 36923419 ↗
L1RCTCited in: Patient Counselling - [70]
Perwaiz A, Gupta A, Mittal V et al.. “Prospective Evaluation of Multimodal Prehabilitation in Esophagogastric Cancer Surgery: Enhancing Patient Outcomes.” World journal of surgery (2025). PMID: 40186345 ↗
L2NON_RANDOMIZED_TRIALCited in: Patient Counselling - [71]
Hansford S, Kaurah P, Li-Chang H et al.. “Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.” JAMA oncology (2015). PMID: 26182300 ↗
L5OTHERCited in: Patient Counselling - [72]
Kang S, Kim DH, Kim NH et al.. “Clinical Outcomes and Prognostic Factors in Older Adult Patients Aged ≥75 Years With Early Gastric Cancer After Endoscopic Resections: A Nationwide Cohort Study.” Journal of gastric cancer (2026). PMID: 42411165 ↗
L3COHORTCited in: Patient Counselling - [73]
Fujiya K, Fuseya H, Yonenaga Y et al.. “Association of a Multimodal Perioperative Care Program With Postoperative Complications in Elderly Patients Undergoing Gastrectomy for Gastric Cancer.” Annals of gastroenterological surgery (2026). PMID: 42395131 ↗
L3COHORTCited in: Patient Counselling
Backlinks
- ← Gastric Cancer (Detailed)
- ← Gastric Cancer Radiation Management (Detailed)
- ← Gastric Cancer Palliative Care
- ← Gastric Cancer Palliative Care (Detailed)
- ← Gastric Cancer Surgical Management
- ← Gastric Cancer Recurrent and Metastatic Disease (Detailed)
- ← Gastric Cancer Systemic Therapy (Detailed)
- ← Gastric Cancer Radiation Management
- ← Gastric Cancer Recurrent and Metastatic Disease
- ← Gastric Cancer Surgical Management (Detailed)